A5016994074- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- Syphilis Diagnosis and Treatment
- HIV Research and Treatment
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Transgenic Plants and Applications
- Poxvirus research and outbreaks
- Drug-Induced Ocular Toxicity
- Sirtuins and Resveratrol in Medicine
- vaccines and immunoinformatics approaches
- Liver Disease Diagnosis and Treatment
- Herpesvirus Infections and Treatments
- Bacillus and Francisella bacterial research
- HIV/AIDS drug development and treatment
Immune Regulation (United Kingdom)
2024
Wroclaw Medical University
2020-2024
Abstract The occurrence of HIV-1 subtypes differs worldwide and within Europe, with non-B variants mainly found across different exposure groups. In this study, we investigated the distribution temporal trends in subtype variability Poland between 2015 2019. Sequences pol gene fragment from 2518 individuals were used for analysis prevalence. Subtype B was dominant (n = 2163, 85.90%). proportion B-infected decreased significantly, 89.3% to 80.3% This related increasing number A infections....
The introduction of protective vaccination against COVID-19 was a turning point in the fight pandemic. Expectations also concerned effectiveness vaccines inducing strong immune response SARS-CoV-2 virus and length post-vaccination immunity. This topic seems to be especially important case immunocompromised people such as those living with HIV (PLWH). aim study examine concentration anti-SARS-CoV-2 IgG antibodies S1 subunit virus’spike protein marker humoral interferon-gamma (IFN-γ) an...
Background/Objectives: People living with HIV (PLWH) treated combined antiretroviral therapy (cART) show a greater predisposition to metabolic and inflammatory disturbances compared the general population. This study aimed assess effect of five years cART use on level selected parameters related carbohydrate lipid metabolism inflammation in PLWH uninfected. Methods: The levels sirtuins (-1, -3, -6); irisin (IRS); myostatin (MSTN); peptide YY (PYY); glucagon-like peptide-1 (GLP-1); dipeptidyl...
Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have already infected more than 0.7 billion people and caused over 7 million deaths worldwide. At the same time, our knowledge about this virus is still incipient. In some cases, there a pre-pandemic immunity, however its source unknown. analysis of patients’ humoral responses might shed light on puzzle. paper, we evaluated antibody recognition nucleocapsid protein, one structural proteins SARS-CoV-2. For purpose, used...
A large number of monkeypox (MPOX) cases have been reported in Europe and North America 2022, a new outbreak this disease was declared. We describe case patient with probable during the height epidemic Poland. The patient’s symptoms resolved within two weeks, but over next months, he developed community-acquired pneumonia requiring hospitalization and, subsequently, non-specific pleuritis. simultaneous occurrence such severe infections previously healthy young man is not typical suggests...
Covid-19 is caused by a new virus and no effective therapy available. The following article presents the case of 47-year-old woman with SARS-CoV-2 infection. infection was initially mild but because exacerbation symptoms: cough, fever, headache, extreme weakness she admitted to hospital. chest X-ray revealed pneumonia due Covid-19, that why CT not done. Due persistent symptoms infection, containing chloroquine azithromycin introduced, obtaining very quick improvement in condition infected...
Background: The presence and level of anti-SARS-CoV-2 antibodies in PLWH from the Lower Silesia region Poland. Material Methods: A total 216 serum samples both sexes, aged 21–77, treated with TDF or TAF together FTC INSTI at two points time. Anyone who did not experience COVID-19 symptoms. Samples were checked for levels regarding CD4 + T CD8 cells counts, ratio these cells, age, sex, VL, type tenofovir used. Results: average prevalence during first wave 65.81 IU/mL 4.17%, while second wave,...